Treatment options in relapsed NLHPL
| Treatment options in relapsed NLHPL from least to most aggressive . |
|---|
| Active surveillance* |
| Anti-CD20 antibody† |
| Radiotherapy‡ |
| Conventional chemotherapy§ |
| HDCT + ASCTe |
| Treatment options in relapsed NLHPL from least to most aggressive . |
|---|
| Active surveillance* |
| Anti-CD20 antibody† |
| Radiotherapy‡ |
| Conventional chemotherapy§ |
| HDCT + ASCTe |
Sometimes a period of active surveillance can be helpful to get an indication of the rate of progression without treatment.
No evidence that a specific anti-CD20 antibody is superior.
Useful on its own in localized relapse or in combination with other modalities.
Especially useful when not received yet by the patient; consider ABVD ± rituximab, R-CHOP, BEACOPP variants ± rituximab, BR, and R-CVP.
No evidence that a specific salvage regimen is superior. Reasonable options are, among others, R-DHAP, R-ESHAP, R-ICE, and R-IGEV, and choice should be guided by individual patient susceptibility to specific toxicities and local experience.
R-DHAP, rituximab, dexamethasone, cytarabine, cisplatin; R-ESHAP, rituximab, etoposide, methylprednisolone, cytarabine, cisplatin; R-ICE, rituximab, ifospfamide, carboplatin, etoposide; R-IGEV, rituximab, ifosfamide, gemcitabine, vinorelbine, prednisone.